Jul 7, 2026 04:30PM
Jun 25, 2026 07:05AM
Jun 24, 2026 04:05PM
May 29, 2026 07:00AM
May 15, 2026 06:01AM
Apr 15, 2026 06:06AM
Apr 9, 2026 06:55AM Northland Starts ARS Pharmaceuticals Inc (SPRY) at Outperform, 'Disrupting the Injectable Epinephrine Market'
Mar 27, 2026 09:49AM
Mar 10, 2026 06:22AM
Mar 9, 2026 08:01AM
Mar 2, 2026 06:37AM
Dec 29, 2025 08:00AM
Nov 10, 2025 07:29AM
Nov 10, 2025 07:28AM Raymond James Reiterates Strong Buy Rating on ARS Pharmaceuticals Inc (SPRY)
Nov 10, 2025 06:09AM
Nov 4, 2025 07:58AM
Oct 8, 2025 08:00AM
Sep 29, 2025 04:06PM
Sep 26, 2025 09:31AM
Sep 19, 2025 08:01AM
Sep 4, 2025 09:27AM Roth/MKM Starts ARS Pharmaceuticals Inc (SPRY) at Buy, 'Game Changer for the Epinephrine Market'
Aug 14, 2025 05:50AM
Aug 13, 2025 07:09AM
Jul 18, 2025 09:26AM
Jun 30, 2025 06:02AM
May 14, 2025 04:13PM
May 14, 2025 10:22AM
Mar 31, 2025 06:19AM Raymond James Reiterates Strong Buy Rating on ARS Pharmaceuticals Inc (SPRY), PT $32
Mar 24, 2025 05:24AM
Mar 20, 2025 10:06AM
Mar 7, 2025 07:07AM
Mar 5, 2025 04:11PM
Jan 6, 2025 08:10AM
Dec 12, 2024 02:33PM
Nov 11, 2024 07:03AM ARS Pharmaceuticals (SPRY) Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy in Europe, Canada and Other Geographies
Sep 23, 2024 08:12AM
Sep 9, 2024 04:47PM
Aug 26, 2024 09:31AM
Aug 19, 2024 11:44PM
Aug 9, 2024 12:50PM
Aug 7, 2024 04:55AM
Jun 28, 2024 06:30AM ARS Pharmaceuticals (SPRY) Announces EURneffy Recommended for Approval by CHMP

417,310 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All